U-Turn: NICE Recommends Rituximab, Humira In Arthritis Indications After Second Review
This article was originally published in The Pink Sheet Daily
Executive Summary
U.K. agency reverses unfavorable preliminary opinions based on submissions from Roche and Abbott.
You may also be interested in...
European HTA: Cancer Drugs Suffer At NICE, Whilst IQWiG And HAS Also Tighten Purse Strings
Economic austerity and the resulting pressure on health care spend leaves little room for maneuver among Europe’s health technology assessment agencies.
NICE Seeks More Data From Abbott On Humira In Psoriatic Arthritis
U.K. agency’s preliminary appraisal on cost effectiveness does not call for recommending adalimumab.
NICE Says Sequential Use Of TNF Inhibitors To Treat RA Is Not Cost Effective
The agency, however, recommends use of Abbott's Humira, Wyeth's Enbrel and Johnson & Johnson's Remicade to treat RA.